The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
CpG DNA as a vaccine adjuvant
Open accessAbstract
Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs trigger cells that express Toll-like receptor 9 (including human plasmacytoid dendritic cells and B cells) to mount an innate immune response characterized by the production of Th1 and proinflammatory cytokines. When used as vaccine adjuvants, CpG ODNs improve the function of professional antigen-presenting cells and boost the generation of humoral and cellular vaccine-specific immune responses. These effects are optimized by maintaining ODNs and vaccine in close proximity. The adjuvant properties of CpG ODNs are observed when administered either systemically or mucosally, and persist in immunocompromised hosts. Preclinical studies indicate that CpG ODNs improve the activity of vaccines targeting infectious diseases and cancer. Clinical trials demonstrate that CpG ODNs have a good safety profile and increase the immunogenicity of coadministered vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 6×
“Only transfection with TLR-9 conferred responsiveness to CpG ODNs or bacterial DNA [9,10].”
BackgroundInfluentialDirect Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
Self-citationPathogen Recognition and Inflammatory Signaling in Innate Immune Defenses
Mogensen, T. H. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-08 · Cited by 3,111
Toll-like receptors in the induction of the innate immune response
Aderem, A., & Ulevitch, R. J. (2000) · Nature · doi:10.1038/35021228 · Cited by 3,064
Recognition of microorganisms and activation of the immune response
Medzhitov, R. (2007) · Nature · doi:10.1038/nature06246 · Cited by 2,862
CpG Motifs in Bacterial DNA and Their Immune Effects
Krieg, A. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064842 · Cited by 2,573
Innate Immunity: The Virtues of a Nonclonal System of Recognition
Medzhitov, R., & Janeway, C. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80412-2 · Cited by 2,434
Research works printed but not linked: 22
- Paul WE. Fundamental Immunology . Raven Press, New York, NY, USA (1993).
- Tross, 2008, J. Immunol., 181, 5785, 10.4049/jimmunol.181.8.5785 · doi:10.4049/jimmunol.181.8.5785
- 10.4049/jimmunol.168.12.6099 · doi:10.4049/jimmunol.168.12.6099
- Sandler, 2003, Cancer Res., 63, 394
- von Hunolstein, 2001, Vaccine, 19, 3058, 10.1016/S0264-410X(01)00048-2 · doi:10.1016/s0264-410x(01)00048-2
- Al Mariri, 2001, Infect. Immun., 69, 4816, 10.1128/IAI.69.8.4816-4822.2001 · doi:10.1128/iai.69.8.4816-4822.2001
- Klinman, 2007, Microbes Infect., 9, 1478, 10.1016/j.micinf.2007.08.002 · doi:10.1016/j.micinf.2007.08.002
- Qin, 2004, Cell. Mol. Immunol., 1, 148
- Diamant, 1993, Pediatr. Infect. Dis. J., 12, 877, 10.1097/00006454-199310000-00014 · doi:10.1097/00006454-199310000-00014
- Wong, 1996, Int. J. STD AIDS, 7, 490, 10.1258/0956462961918563 · doi:10.1258/0956462961918563
- Linghua, 2007, Vet. Immunol. Immunopathol., 115, 216, 10.1016/j.vetimm.2006.10.017 · doi:10.1016/j.vetimm.2006.10.017
- Davis, 2000, Vaccine, 18, 1920, 10.1016/S0264-410X(99)00443-0 · doi:10.1016/s0264-410x(99)00443-0
- Steinhagen, 2010, Vaccine
- 10.1172/JCI23373 · doi:10.1172/jci23373 · Paper page
- Steinberg, 1990, Immunol. Rev., 118, 129, 10.1111/j.1600-065X.1990.tb00815.x · doi:10.1111/j.1600-065x.1990.tb00815.x
- Klinman, 1990, J. Clin. Invest., 86, 1249, 10.1172/JCI114831 · doi:10.1172/jci114831
- Yi, 1996, J. Immunol., 157, 4918, 10.4049/jimmunol.157.11.4918 · doi:10.4049/jimmunol.157.11.4918
- Katsumi, 1994, Hum. Gene Ther., 5, 1335, 10.1089/hum.1994.5.11-1335 · doi:10.1089/hum.1994.5.11-1335
- Gilkeson, 1998, J. Immunol., 161, 3890, 10.4049/jimmunol.161.8.3890 · doi:10.4049/jimmunol.161.8.3890
- 10.1038/nbt0508-484a · doi:10.1038/nbt0508-484a
- Le, 1999, J. Rheumatol., 26, 191
- Allen, 1993, Thorax, 48, 580, 10.1136/thx.48.5.580 · doi:10.1136/thx.48.5.580
Cited by
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Immunotherapeutic uses of CpG oligodeoxynucleotides
Klinman, D. M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1329 · Cited by 1,012
Self-citationStructure-based programming of lymph-node targeting in molecular vaccines
Liu, H., Moynihan, K. D., Zheng, Y., Szeto, G. L., Li, A. V., Huang, B., Van Egeren, D. S., Park, C., & Irvine, D. J. (2014) · Nature · doi:10.1038/nature12978 · Cited by 943
Compound Copper Chalcogenide Nanocrystals
Coughlan, C., Ibáñez, M., Dobrozhan, O., Singh, A., Cabot, A., & Ryan, K. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00376 · Cited by 930
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
Guo, L., Yan, D. D., Yang, D., Li, Y., Wang, X., Zalewski, O., Yan, B., & Lu, W. (2014) · ACS Nano · doi:10.1021/nn5002112 · Cited by 532
Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity
Kroll, A. V., Fang, R. H., Jiang, Y., Zhou, J., Wei, X., Yu, C. L., Gao, J., Luk, B. T., Dehaini, D., Gao, W., et al. (2017) · Advanced Materials · doi:10.1002/adma.201703969 · Cited by 501
Modern Subunit Vaccines: Development, Components, and Research Opportunities
Moyle, P. M., & Toth, I. (2013) · ChemMedChem · doi:10.1002/cmdc.201200487 · Cited by 464
Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity
Shi, S., Zhu, H., Xia, X., Liang, Z., Ma, X., & Sun, B. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.055 · Cited by 423
Advances in Non-Viral DNA Vectors for Gene Therapy
Hardee, C., Arévalo-Soliz, L., Hornstein, B., & Zechiedrich, L. (2017) · Genes · doi:10.3390/genes8020065 · Cited by 356
Recent Progresses in Phototherapy‐Synergized Cancer Immunotherapy
Ng, C. W., Li, J., & Pu, K. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201804688 · Cited by 349
Scheiermann, J., & Klinman, D. M. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.06.065 · Cited by 322
Self-citationWilson, J. T., Keller, S., Manganiello, M. J., Cheng, C., Lee, C.-C., Opara, C., Convertine, A., & Stayton, P. S. (2013) · ACS Nano · doi:10.1021/nn305466z · Cited by 317
Adjuvants and immunostimulants in fish vaccines: Current knowledge and future perspectives
Tafalla, C., Bøgwald, J., & Dalmo, R. A. (2013) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2013.02.029 · Cited by 311
An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy
Bonam, S. R., Partidos, C. D., Halmuthur, S. K. M., & Muller, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.002 · Cited by 261
Recent progress in adjuvant discovery for peptide-based subunit vaccines
Azmi, F., Ahmad Fuaad, A. A. H., Skwarczynski, M., & Toth, I. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.27332 · Cited by 239
Sweeten PAMPs: Role of sugar complexed PAMPs in innate immunity and vaccine biology
Mahla, R. S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00248 · Cited by 239
Yoshida, S., Nakagami, H., Hayashi, H., Ikeda, Y., Sun, J., Tenma, A., Tomioka, H., Kawano, T., Shimamura, M., Morishita, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16347-w · Cited by 161
Kwissa, M., Nakaya, H. I., Oluoch, H., & Pulendran, B. (2012) · Blood · doi:10.1182/blood-2011-10-388579 · Cited by 132
Peptide-based vaccine for cancer therapies
Buonaguro, L., & Tagliamonte, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1210044 · Cited by 110
Codon Modification and PAMPs in Clinical AAV Vectors: The Tortoise or the Hare?
Wright, J. F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.026 · Cited by 80
Quantification of CpG motifs in rAAV genomes: Avoiding the toll
Wright, J. F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.07.006 · Cited by 65
Clauson, R. M., Berg, B., & Chertok, B. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00091 · Cited by 20
Metadata
- Authors
- Bode, C., Zhao, G., Steinhagen, F., Kinjo, T., & Klinman, D. M.
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2011-04
- Volume
- 10
- Issue
- 4
- Pages
- 499-511
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- OpenAlex
- W2110223801
- Cited by
- 891
- References
- 174
- FWCI
- 18.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.